Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.33 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.33 |
| ▸ | NR2C2 | P49116 | 2/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873944 | 0.81 | ALOX15 (0.35) | ALOX15TSHRPOLBCYP19A1TAS2R46 | |
| SCHEMBL17530290 | 0.79 | ALOX15 (0.41) | ALOX15TSHRCA1CA2POLB | |
| SCHEMBL8873959 | 0.74 | ALOX15 (0.39) | ALOX15TSHRPOLBCYP19A1TAS2R46 | |
| SCHEMBL19409297 | 0.72 | POLB (0.45) | ALOX15TSHRPOLB | |
| SCHEMBL31305277 | 0.72 | ALOX15 (0.37) | ALOX15TSHRCA1CA2POLB | |
| SCHEMBL4273415 | 0.71 | CYP19A1 (0.40) | ALOX15TSHRPOLBCYP19A1USP2 | |
| SCHEMBL8654077 | 0.69 | CYP3A4 (0.35) | ALOX15TSHRPOLBCYP3A4 | |
| SCHEMBL3630845 | 0.68 | — | — | |
| SCHEMBL14354717 | 0.64 | CHRM2 (0.42) | ALOX15TSHRPOLB | |
| SCHEMBL880204 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2024-08-06 | — | — | US | disclosed |
| CN-109415387-B | Arginase inhibitors and therapeutic uses thereof | 昂科艾伦迪治疗法公司 | 2021-08-27 | — | — | CN | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| EP-3452485-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2020-09-09 | — | — | EP | disclosed |
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2019-08-27 | — | — | US | disclosed |
| EP-3452485-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Oncoarendi Therapeutics SA (PL) | 2019-03-13 | — | — | EP | disclosed |
| EP-3227279-B1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | LILLY CO ELI (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017191130-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017191130-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| EP-3227279-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | Eli Lilly and Company (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9776992-B2 | 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776992-B2 | 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776992-B2 | 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | ALOX15 1439/4885TSHR 1664/4885CA1 2313/4885 |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | ALOX15 1439/4885TSHR 1664/4885CA1 2313/4885 |
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | CDKN1A, API5, NUTF2 | ALOX15 4010/4885TSHR 4246/4885CA1 3903/4885 |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | ALOX15 1439/4885TSHR 1664/4885CA1 2313/4885 |
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | ALOX15 1439/4885TSHR 1664/4885CA1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.